A Phase 2 Open-label, Dose-finding Study to Determine the Optimal Dose for Lymph Node Visualization Using ASP5354 in Participants With Breast Cancer or Melanoma Undergoing Sentinel Lymph Node Biopsy
Latest Information Update: 08 May 2024
At a glance
- Drugs Pudexacianinium (Primary) ; Pudexacianinium (Primary)
- Indications Early breast cancer; Malignant melanoma
- Focus Diagnostic use
- Sponsors Astellas Pharma
Most Recent Events
- 11 Dec 2023 Status changed from recruiting to discontinued.
- 04 Sep 2022 Planned End Date changed from 28 Feb 2023 to 30 Sep 2023.
- 04 Sep 2022 Planned primary completion date changed from 28 Feb 2023 to 30 Sep 2023.